Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies after COVID-19 Booster Vaccines – The CoVVacBoost Study - The CoVVacBoost Study

Medical University of Graz0 个研究点目标入组 1,200 人开始时间: 2021年11月16日最近更新: 2021年12月21日

适应症

试验速览

暂无简介。

•Participants must be 18 years or older, able to understand study procedures, provide written informed consent (Biobank informed consent and study specific informed consent), and meet the following inclusion criteria:
•1. Healthy Individuals who received full vaccination with any authorized COVID-19 vaccine and decided to receive a booster vaccination as recommended by national guidelines.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 1000
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 200

•1.Presence of diseases or therapies that are likely to interfere with the immune response to booster vaccination.
•2.Any contraindications to the vaccine planned to receive as listed in the product characteristics.
•3.Lack of willingness to undergo serial blood draws and attend follow-up appointments.
•4.Having already received a third (booster) vaccination with any COVID-19 vaccine.
•5.Women who are pregnant or breastfeeding.
•6.Persons who are not willing to sign the informed consents (biobank informed consent and study specific informed consent)

发起方

Medical University of Graz